Haloperidol Decanoate

CHEMBL1200986 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

530.1 g/mol

LogP

7.9

Phase

4

A long-acting injectable formulation of haloperidol in which the drug is esterified with decanoic acid to create a depot preparation administered every two to four weeks for the maintenance treatment of schizophrenia and bipolar disorder. This formulation improves medication adherence by eliminating the need for daily dosing. It provides sustained antipsychotic coverage, making it particularly valuable for patients with a history of non-compliance.

分子量

530.1000 g/mol

LogP

7.90

TPSA

46.60 Å²

リピンスキーの五則

不適合

治療領域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Pain Management Non-Small Cell Lung Cancer Alzheimer's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Chronic Kidney Disease Stroke Obesity Type 2 Diabetes Hypertension Breast Cancer Chronic Pain Heart Failure Prostate Cancer Colorectal Cancer

作用機序

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1

InChI

InChI=1S/C31H41ClFNO3/c1-2-3-4-5-6-7-8-11-30(36)37-31(26-14-16-27(32)17-15-26)20-23-34(24-21-31)22-9-10-29(35)25-12-18-28(33)19-13-25/h12-19H,2-11,20-24H2,1H3

Molecular Formula

C31H41ClFNO3

HBD / HBA

- / 5

回転可能結合数

16

重原子数

37

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A long-acting injectable formulation of haloperidol in which the drug is esterified with decanoic acid to create a depot preparation administered every two to four weeks for the maintenance treatment of schizophrenia and bipolar disorder. This formulation improves medication adherence by eliminating the need for daily dosing. It provides sustained antipsychotic coverage, making it particularly valuable for patients with a history of non-compliance.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Haloperidol Decanoate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200986. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 52919. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Haloperidol Decanoate PillFYIで

構造

クイックデータ

分子式: C31H41ClFNO3
同義語: 1

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.